Investors might want to bet on Marex Group PLC (MRX) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individua ...

ACNB (ACNB) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual investors often fi ...

Investors might want to bet on Rapt Therapeutics (RAPT) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the sys ...

Cellectar Biosciences, Inc. (CLRB) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Th ...

Amgen (AMGN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a chang ...

核心观点 - Sprout Social (SPT) 近期被上调至 Zacks Rank 1 (强力买入) 评级 这反映了其盈利预期的上升趋势 而盈利预期是影响股价的最强大因素之一 [1][3] - Zacks 评级体系基于分析师对当前及未来年度每股收益(EPS)预期的共识 即 Zacks Consensus Estimate [1] - 盈利预期的变化与股价短期走势高度相关 机构投资者利用盈利预期计算公司股票的合理价值 从而推动买卖行为 [4] - 过去三个月 Sprout Social 的 Zacks Consensus Estimate 已上升13.8% 显示分析师对其盈利前景持续看好 [8] Zacks 评级体系 - Zacks 评级系统使用四个与盈利预期相关的因素 将股票分为五类 从 Zacks Rank 1 (强力买入) 到 Zacks Rank 5 (强力卖出) [7] - 自1988年以来 Zacks Rank 1 股票的平均年回报率为+25% [7] - Zacks 评级系统覆盖超过4000只股票 在任何时候都保持"买入"和"卖出"评级的均衡比例 只有前5%的股票能获得"强力买入"评级 [9][10] Sprout Social 的盈利前景 - 这家云软件开发商预计在2025财年每股收益为0.73美元 与上年相比没有变化 [8] - 公司被上调至 Zacks Rank 1 意味着其盈利预期修订表现位于所有被覆盖股票的前5% 表明其可能在短期内跑赢市场 [10] - 盈利预期的上升和评级上调反映了公司基本业务的改善 投资者可能会因此推高股价 [5] 盈利预期修订与股价关系 - 实证研究表明 盈利预期修订趋势与股价短期走势存在强相关性 [6] - 机构投资者通过调整估值模型中的盈利预期来改变对股票合理价值的判断 进而进行大规模买卖 导致股价变动 [4] - Zacks 评级系统有效利用了盈利预期修订的力量 帮助投资者做出投资决策 [6]

核心观点 - Phreesia(PHR)近期被上调至Zacks Rank 2(买入评级) 主要反映其盈利预期的上升趋势 这是影响股价的最强动力之一 [1] - Zacks评级完全基于公司盈利预期的变化 通过追踪卖方分析师对当前及下一财年EPS预测的共识值(Zacks共识预期)来衡量 [1] - 盈利预期的变化与短期股价走势高度相关 机构投资者利用盈利预期计算股票公允价值 其大规模交易直接推动股价变动 [4] - Phreesia的评级上调意味着市场对其盈利前景持乐观态度 可能转化为买入压力并推高股价 [3] 评级体系特征 - Zacks评级系统将股票分为5个等级(从强力买入到强力卖出) 仅覆盖股票中前5%给予"强力买入"评级 前15%-20%给予"买入"评级 [9] - 该系统保持覆盖的4000多只股票中"买入"和"卖出"评级比例均衡 不受市场条件影响 [9] - Zacks Rank 1股票自1988年以来年均回报率达+25% 具有经外部审计的优秀历史记录 [7] Phreesia财务数据 - 截至2026年1月的财年 这家医疗软件开发商预计每股亏损0.17美元 与上年持平 [8] - 过去三个月 Zacks共识预期上调41.5% 显示分析师持续调高盈利预测 [8] - 当前评级表明该股在Zacks覆盖股票中处于前20% 具备超越市场平均回报的潜力 [10] 盈利预期修正机制 - 实证研究显示盈利预期修正趋势与短期股价波动存在强相关性 [6] - 机构投资者通过估值模型调整盈利预期 直接影响其对股票公允价值的判断 进而引发买卖行为 [4] - Zacks评级系统有效利用盈利预期修正的规律 为投资决策提供量化依据 [6]

Exact Sciences (EXAS) closed the last trading session at $54.3, gaining 1.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $68.55 indicates a 26.2% upside potential.The average comprises 22 short-term price targets ranging from a low of $54.00 to a high of $90.00, with a standard deviation of $7.85. While the lowest estimate indicates a decline of 0.6% from the current price leve ...

股价目标分析 - Astrana Health(ASTH)最新收盘价为25 12美元 过去四周涨幅0 7% 华尔街分析师给出的平均目标价49 56美元 隐含97 3%上行空间 [1] - 9位分析师目标价区间为36-70美元 标准差12 39美元 最低目标价隐含43 3%涨幅 最高目标价隐含178 7%涨幅 标准差反映分析师预测分歧程度 [2] - 分析师共识目标价存在局限性 其设定能力与客观性长期受质疑 实证研究表明目标价常误导投资者而非提供有效指引 [3][7] 盈利预测修正 - 分析师近期持续上调EPS预测 过去30日内有两项正面修正且无负面修正 推动Zacks共识预期大幅增长46 4% [11][12] - 盈利预测修正趋势与股价短期走势存在强相关性 这成为ASTH潜在上涨的实质性支撑因素 [4][11] - ASTH当前获Zacks排名第一(强烈买入) 位列4000多只股票前5% 该排名基于盈利预测相关四项因子 具有较高参考价值 [13] 分析师行为特征 - 华尔街分析师虽具备基本面分析能力 但常因商业利益(如维护客户关系)设定过度乐观目标价 [8] - 低标准差目标价集群反映分析师对股价方向与幅度存在高度共识 可作为深入研究公司基本面的起点 [9] - 投资者应辩证看待目标价 完全依赖其做决策可能导致投资回报不及预期 需保持审慎态度 [10] 综合评估 - 尽管共识目标价可靠性存疑 但其暗示的股价方向仍具参考意义 结合盈利预测上修与Zacks排名 公司短期存在实质性上涨动力 [14]

Shares of Hillman Solutions Corp. (HLMN) have gained 13.1% over the past four weeks to close the last trading session at $7.77, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $10.94 indicates a potential upside of 40.8%.The mean estimate comprises eight short-term price targets with a standard deviation of $2.54. While the lowest estimate of $8.00 indicates a 3% increase from t ...